

## **Cultural adaptation of the female pelvic floor questionnaire (FPFQ) into French**

Julia Deparis, Véronique Bonniaud, David Desseauve, Joëlle Guilhot, Margot Masanovic, Renaud De Tayrac, Arnaud Fauconnier, Xavier Fritel

► **To cite this version:**

Julia Deparis, Véronique Bonniaud, David Desseauve, Joëlle Guilhot, Margot Masanovic, et al.. Cultural adaptation of the female pelvic floor questionnaire (FPFQ) into French. *Neurourology and Urodynamics*, Wiley, 2015. <inserm-01262619>

**HAL Id: inserm-01262619**

**<http://www.hal.inserm.fr/inserm-01262619>**

Submitted on 26 Jan 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Title page**

2 Cultural adaptation of the female pelvic floor questionnaire (FPFQ) into French

3 **Authors**

4 Deparis Julia, 1

5 Bonniaud Véronique, 2

6 Desseauve David, 1

7 Guilhot Joëlle, 3

8 Masanovic Margot, 4

9 De TAYRAC Renaud, 5

10 Fauconnier Arnaud, 6

11 Fritel Xavier, 1, 3

12 **Institutions**

13 *1. Université de Poitiers, Faculté de Médecine et Pharmacie, CHU de Poitiers, Poitiers, France*

14 *2. Réseau de Pelvi-Périnéologie, Rééducation, Centre Hospitalier Universitaire de Dijon, Dijon,*

15 *France*

16 *3. INSERM CIC 1402, CHU de Poitiers, Poitiers, France*

17 *4. Centre Hospitalier Universitaire de La Réunion, Saint-Denis, France*

18 *5. Centre Hospitalier Universitaire de Nîmes, Nîmes, France*

19 *6. Centre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Poissy, France ; Research*

20 *unit EA 7285 (RISCQ), Université Versailles St-Quentin, 78180 Montigny-le-Bretonneux, France*

21 **Short title:** Female Pelvic Floor Questionnaire French Validation

22 **Correspondance**

23 Julia Deparis, Ecole de sages-femmes, CHU de Poitiers, 2 rue de la Milétrie, 86000 Poitiers,

24 France ; [julia.deparis@chu-poitiers.fr](mailto:julia.deparis@chu-poitiers.fr) ; telephone number 05-49-44-33-32 / 06-71-74-11-79

25 **Manuscript word count:** 3106 words

26 **Abstract**

27 **Aims:** The Female pelvic floor questionnaire (FPFQ) is a self-administered tool on pelvic floor  
28 function. Our aim was to carry out a cultural adaptation of the FPFQ into French and to  
29 assess its psychometric properties.

30 **Methods:** After cross-cultural adaptation into French, acceptability and reliability of the  
31 questionnaire were assessed through a sample of 56 women in a test-retest. Discriminative  
32 construct validity was evaluated by comparing the results obtained by the FPFQ to those of  
33 other validated questionnaires. Longitudinal follow-up of the 282 pregnant women included  
34 in the PreNatal Pelvic floor Prevention trial (3PN) was used to analyze responsiveness.

35 **Results:** The proportion of missing data did not exceed 4% for questions about bladder  
36 function, bowel function and pelvic organ prolapse; 10% for issues related to sexual  
37 function. Question 9 was considered difficult to understand by 14% of women. After  
38 rewriting, this issue was retested in a new sample of 52 women and presented no further  
39 problems. The intra-class correlation coefficient was greater than or equal to 0.7 for all  
40 domains during the test-retest. The FPFQ was strongly and significantly correlated  
41 (Spearman  $r > 0.5$ ) with the other validated questionnaires. The French version of FPFQ  
42 recorded changes in urinary and sexual symptoms for the women involved in 3PN trial with  
43 a standardized response mean equal to 0.83 and 0.44, respectively.

44 **Conclusion:** The French version of the FPFQ is self-administered, reliable, valid, and can  
45 detect a change in symptoms during follow-up.

46 **Key Words:** Pelvic floor – Symptoms – Questionnaire – Validation studies – French

47

## 48 **Introduction**

49 Pelvic floor disorders (PFD) in women are common and debilitating (1). It is estimated that  
50 10-20% of women will be operated upon during their lifetime for these disorders (2). They  
51 can result in different pelvic-perineal symptoms affecting all areas of the anatomy such as  
52 voiding and anorectal difficulties, incontinence, prolapse and sexual disorders. These  
53 symptoms are often associated; 25% of patients consulting for genitourinary prolapse also  
54 suffer terminal constipation, and 33% from anal incontinence (3). They can cause functional  
55 difficulties beyond the organ concerned, for example urinary incontinence affects sexual  
56 satisfaction (4). Studies have demonstrated that treatment for one symptom can improve,  
57 worsen or even predispose another (5). Epidemiologists as clinicians need tools to assess  
58 the prevalence of symptoms associated with functional PFD and the severity of these  
59 symptoms. Many questionnaires have been developed to assess urinary incontinence (6)  
60 and urinary obstruction (7). Questionnaires investigating the symptoms of prolapse (8),  
61 sexual symptoms, anal incontinence or anorectal obstruction exist but are slightly less  
62 common (9). The Female Pelvic Floor Questionnaire (FPFQ) developed by Kaven Baessler  
63 explores all aspects of pelvic floor dysfunction: bladder, bowel, prolapse and sexual  
64 symptoms. This questionnaire was designed for the "Longitudinal Assessment of Woman"  
65 study conducted by the Betty Byrne Henderson research center in Brisbane, to collect  
66 longitudinal data on the incidence and prevalence of PFD in community-dwelling women  
67 (10). The reliability, validity and responsiveness of the tool were developed during two  
68 different studies (11,12). This questionnaire was originally in English and adapted into  
69 German (13). Translating and culturally adapting a questionnaire into another language is  
70 more interesting than creating a new instrument. This method makes it possible to compare

71 results across studies, despite different languages and cultures because the data comes  
72 from the same instrument. It also allows the study to be carried out on a larger scale with  
73 international participation. After translating and cultural adaptation, it is necessary to  
74 ensure the equivalence of the concept measured by the questionnaire through the analysis  
75 of its psychometric properties. The questionnaire must be acceptable to make data  
76 collection possible. It must be reliable and valid to properly discriminate between subjects,  
77 establish a profile or identify determining factors. To detect a change in the  
78 symptomatology of an individual in a longitudinal comparison, this tool must be sensitive to  
79 changes (14).

80 The aim of our study was to carry out the cultural adaptation of the FPFQ into French in two  
81 stages: translation and validation of the questionnaire to ensure cross-cultural relevance  
82 and conceptual equivalence with the original questionnaire.

## 83 **Method**

84 The FPFQ is a self-administered questionnaire with 37 questions. Thirty-three of them  
85 assess symptoms in 4 areas (bladder, bowel, prolapse and sexual function section) and 4  
86 questions investigate the inconvenience caused by these symptoms in each area (11). Each  
87 question has four possible answers of increasing severity (usually *never*, *occasionally*,  
88 *frequently* or *daily*). It is possible to calculate a 10 point subscore for each area. Each sub-  
89 score is the sum of the marks obtained in each section of questions divided by the maximum  
90 number of points, multiplied by 10. The addition of these four subscores provides a total  
91 score out of 40. The higher this score, the more the woman suffers from PFD.

### 92 ***Cross-cultural adaptation***

93 After obtaining the agreement from the author (Kaven Baessler) to perform the cultural  
94 adaptation of the FPFQ into French, three translations of the English version were  
95 performed independently by a urogynaecologist (XF), a rehabilitation doctor (MM) and a  
96 female non-doctor, whose native language were French and who had a good knowledge of  
97 English. A summary of these three translations was revised several times by the translators  
98 until a consensus was reached (15). The back-translation was deemed unnecessary to  
99 emphasize the meaning rather than the literal translation. This version was then pre-tested  
100 with 4 French women (none of whom were doctors or caregivers), in individual interviews.

### 101 - ***Validation***

#### 102 - *Reference measurements*

103 Construct validity examines the ability of a questionnaire to measure what it is supposed to  
104 measure. It studies the correlations between the questionnaire scores and other reference  
105 measurements at a particular point in time (14). Five other questionnaires already validated

106 in French were chosen as reference measurement in this analysis: The ICIQ-UI-SF  
107 (International Consultation on Incontinence Questionnaire - Urinary Incontinence Short-  
108 Form) assesses urinary incontinence four questions; The IPSS (International Prostate  
109 Symptom Score) evaluates voiding difficulties via 8 questions; Contilife, a quality of life  
110 questionnaire adapted for women with urinary incontinence, comprises 28 questions  
111 divided into six sections; The PFDI-20 (Pelvic Floor Distress Inventory) assesses symptoms of  
112 prolapse and the inconvenience caused by these symptoms and is composed of 20  
113 questions dealing with bladder (UDI-6), bowel (CRADI-8) and to prolapse symptoms (POPDI-  
114 6); The PFIQ-7 (Pelvic Floor Impact Questionnaire) is a questionnaire on the social impact of  
115 prolapse, it examines the severity of bladder (UIQ-7), bowel (CRAIQ-7) and specific prolapse  
116 symptoms (POPIQ- 7) (6-9).

#### 117 - *Populations*

118 Three populations were used to evaluate the questionnaire. Two convenience samples,  
119 composed of easily queryable women in the investigators' entourage, were set up with 56  
120 women in the first sample (No.1) and 52 women in the second (No. 2). Sample No. 1 tested  
121 understanding of the issues (acceptability) and the reliability of the questionnaire through a  
122 test-retest and the construct validity of the bladder section of the FPFQ. The issues deemed  
123 difficult to understand by sample No.1 were reformulated and then re-tested by sample  
124 No.2. Inclusion criteria for these samples were voluntary adult women in the authors'  
125 entourage (regardless of age or occupation) or an adult women consulting for reasons other  
126 than PFD. Women likely to benefit from PFD treatment or intervention were excluded, as  
127 were minors and those with neurological impairment.

128 The 282 pregnant women included in the Prenatal Perineal Prevention (3PN) study also  
129 received the questionnaire. 3PN is a multicenter, randomized study whose main objective  
130 was to compare the effect on urinary incontinence at one year postpartum of prenatal  
131 rehabilitation compared to receiving written information only (16). The data collected  
132 helped analyze the construct validity of specific questions on prolapse and bowel symptoms  
133 but also to explore sensitivity to changes through longitudinal monitoring of these women.

134 - *Administration of the questionnaire*

135 Sample No. 1 - Women completed the self-administered questionnaire twice, one month  
136 apart (test-retest). The first time, they were instructed to report difficulties in understanding  
137 and possibly propose a reformulation of the question. They also completed the  
138 aforementioned reference questionnaires.

139 Sample No. 2 - Issues considered difficult to understand by the women in sample No. 1 were  
140 reformulated and tested in sample No. 2.

141 3PN women were included in the testing during pregnancy and monitored for one year after  
142 childbirth (16). They completed the French version of FPFQ, the ICIQ-IUSF and Contilife  
143 questionnaires four separate times during monitoring. The 71 women enrolled in the 3PN  
144 study in Nîmes University Hospital completed two additional questionnaires covering  
145 prolapse symptoms (PFDI-20 and PFIQ-7).

146 - ***Statistical Analysis***

147 *Acceptability* - The incidence of difficulty understanding questions and the number of  
148 unanswered questions were indicators of acceptability. The non-response rate per question  
149 was calculated from sample No. 1 and from all 3PN patients on the data collected during the  
150 first completion of the FPFQ.

151 *Reliability* - The test-retest performed by sample No. 1 was used to analyze the  
152 reproducibility of the tool in clinically stable women. To compare the scores between the  
153 two evaluations, an intra-class correlation coefficient for sub-scores of each section and the  
154 total score was calculated. A value greater than 0.7 was considered acceptable (17).  
155 Concordance was measured for each FPFQ question component through a weighted Cohen  
156 Kappa coefficient. A Kappa coefficient up to 0.20 is classically poor, from 0.21 to 0.40  
157 mediocre, from 0.41 to 0.60 moderate, from 0.61 to 0.80 good and beyond 0.80 excellent  
158 (18). The Bland-Altman method explored the correlation based on the score obtained (19).

159 *Internal consistency* - This analysis was carried out using data collected from sample No. 1  
160 and 3PN women during the first FPFQ questionnaire. Cronbach's alpha was considered  
161 acceptable from 0.7.

162 *Construct validity* – Data from the FPFQ were compared with reference data collected for  
163 inclusion in sample No. 1 and 71 3PN women at the Nîmes CHU. Longitudinal follow-up of  
164 3PN women allowed the change measured by the FPFQ questionnaire to be compared to  
165 those recorded by the reference measurements between the different assessments.  
166 Calculation of correlations from score differences allows data to be matched. Four statistical  
167 correlation levels were established: strong  $r > 0.5$ ; moderate  $r = 0.36$  to  $0.5$ ; poor  $r = 0.35$  to  
168  $0.2$ ; absent  $r < 0.2$  (20). To assess association strength, the Pearson and Spearman  
169 correlation coefficient was used.

170 Construct validity is far more robust if the investigators establish prior hypotheses about  
171 probable correlations between the test questionnaire and the reference measurements  
172 (14). Seventy-five prior assumptions (using 4 levels of correlation defined in the previous  
173 paragraph) were established on data collected at baseline.

174 *Responsiveness* - Pregnancy and postpartum periods are characterized by a risk of pelvic  
175 floor disorders that are often transient (21). Longitudinal follow-up of 3PN patients was  
176 used to assess changes in pelvic-floor symptoms associated with pregnancy and childbirth.  
177 The degree of variation was assessed by the Standardized Response Mean (RMS) (22).

178 - ***Ethics***

179 All women gave consent before participating. For samples No. 1 and No. 2, women included  
180 did not undergo any intervention or modification of their support related to their  
181 participation. Thus our work complied with French statutes and regulations, which authorise  
182 observational surveys without approval of an ethics committee. Collected data were  
183 processed according to the recommendations of the CNIL (Commission Informatique et  
184 Libertés, French Data Protection Authority- <http://www.cnil.fr/english/>). Questionnaires  
185 used in samples No. 1 and No. 2 were strictly anonymous.

186 The 3PN study received an institutional review board approval by the Comité de Protection  
187 des Personnes Sud-Ouest-et-Outre-Mer in September 2007 (#2007-A00641-52).

188

## 189 **Results**

190 For the translation and cultural adaptation, 6 intermediate versions were needed before  
191 obtaining a version judged to be suitable and consistent with the original questionnaire. The  
192 pre-test did not lead to any changes.

193 The average age of women was 42 years in sample No. 1, 44 years in the second and 29 in  
194 3PN. 3PN women were all nulliparous and the mean parity was 2.0 and 1.3 in samples 1 and  
195 2 respectively. These women had a low symptomatology with an FPFQ total score of less  
196 than 10 out of 40 (Table I-II).

197 *Acceptability* - Of the 56 women in sample No. 1, the proportion of missing data did not  
198 exceed 4% for questions about bladder, bowel and prolapse symptoms; this figure was 10%  
199 for sexuality-related issues. For the 3PN women, the missing data did not exceed 4%  
200 regardless of the type of question. Significantly less information was given in questions  
201 about sexuality than the others, in both samples ( $p < 0.0001$ ). Question 9 "Votre jet urinaire  
202 est-il faible ou prolongé?" was considered difficult to understand by 14% ( $n = 8$ ) of the  
203 women in sample No. 1. According to them, the terms "faible" and "prolongé" had opposite  
204 meanings. This was the literal translation of the original question: "Is your urinary stream /  
205 flow weak or prolonged?". This question was changed as follows: "Votre jet urinaire est-il  
206 faible ou ralenti?" and was retested with sample No. 2. In this new sample, the  
207 reformulated question 9 posed no further problem.

208 *Reliability* - In sample No. 1, 56 women completed the FPFQ once and 51 twice. The  
209 concordance of responses between the two assessments ranged from 58.3% [95% CI 43.2-  
210 72.4] to 94.1% [83.8-98.8] depending on the issues, with a median of 80.0%. Average kappa  
211 was equal to  $0.6 \pm 0.1$  with a minimum of 0.3 [95% CI 0.1-0.4] and a maximum of 0.8 [95% CI

212 0.6-1.0]. The intraclass correlation coefficient was greater than or equal to 0.7 for the  
213 overall score and each sub-domain (Table I). On average, the change in the FPFQ total score  
214 and subscores was less than 10% between the two assessments (Table I). The Bland-Altman  
215 test was able to identify a lower response concordance among the most symptomatic  
216 women with a marked increase in the difference in overall score in women with a score  
217 higher than 6 out of 40 (Figure 1).

218 *Internal consistency* - Internal consistency was satisfactory with a Cronbach  $\alpha$ -factor greater  
219 than 0.7 for all areas of the FPFQ in sample No. 1 (Table I) and in the 3PN sample (Table II).

220 *Construct validity* - The FPFQ was strongly and significantly correlated (Spearman  $r > 0.5$ )  
221 with the ICIQ-UI-SF ( $r = 0.7$ ), the IPSS ( $r = 0.7$ ) and Contilife ( $r = -0.7$ ) in sample No. 1. Strong  
222 and significant correlations were also found in 3PN women recruited in Nimes, between the  
223 FPFQ and other reference tests (Table III). The kinetics of the scores during the longitudinal  
224 study was similar between the various assessment tools (Figure 2). The differences in scores  
225 recorded by the FPFQ were highly correlated with those measured by ICIQ-UI-SF, Contilife  
226 and PFDI-20. Correlations were lower ( $r$  between 0.1 and 0.6 depending on the section)  
227 between the FPFQ and PFIQ-7 (details not shown).

228 Correlations between the FPFQ and the reference measurements were consistent with the  
229 assumptions in 15 cases (20%), higher in 56 cases (75%), and lower in 4 cases (5%).

230 *Responsiveness* - 3PN women showed a significant ( $p < .0001$ ) decline in bladder symptoms  
231 between late pregnancy and two months postpartum (SMR = 0.83); increased sexual  
232 symptoms between late pregnancy and two months postpartum (RMS = -0.30;  $p = 0.001$ )  
233 with a significant decrease at 12 months postpartum (SMR = 0.44;  $p < 0.0001$ ). Bowel  
234 symptoms were stable over time with a standardized mean response of less than 0.2

235 between successive assessments. These women had a slight increase in prolapse symptoms  
236 between months 6 and 9 of pregnancy (-0.25;  $p < 0.001$ ). These symptoms then remained  
237 stable during postpartum (SMR  $< 0.2$ ).

238 **Discussion**

239 The results of the FPFQ were significantly and strongly correlated with those found in the  
240 reference tests. Significant changes in bladder and sexual symptomatology were recorded  
241 during longitudinal monitoring of women in the 3PN study.

242 The lack of a specific reference test for sexual symptoms did not assess the construct  
243 validity of this section of the FPFQ. The significant increase in the sexual subscore at 2  
244 months postpartum in 3PN women, however, is an argument for its validation. This increase  
245 is consistent with the increase in prevalence of sexual dysfunction observed after delivery  
246 (23). Despite this limitation, one advantage of our study is that it explores the main  
247 psychometric properties of the French FPFQ, including analysis of sensitivity to changes,  
248 which is rarely performed during the validation of a measurement tool.

249 The proportion of questions unanswered was satisfactory, not exceeding 10% despite the  
250 taboo nature of incontinence. This result obtained from both sample No. 1 and the 3PN  
251 study demonstrates the acceptability of the tool. The wording of questions in the final  
252 version posed no comprehension difficulties. We believe the combination of specialist  
253 translators and a naive translator yielded a translation retaining the meaning of the original  
254 concept in a language understood by the target population. A back-translation was not  
255 deemed necessary. This procedure tends to favor a literal translation that amplifies unclear  
256 language in translations (15). The comprehension difficulties regarding question 9 raised by  
257 sample No. 1 is an illustration of this problem. The literal translation of "weak or prolonged"  
258 into "faible ou prolongé" modified the meaning of the phrase. In French, the term  
259 "prolongé" (prolonged) can have two different meanings: temporally prolonged (lasting  
260 longer than usual) or spatially prolonged (extended in distance). This second interpretation

261 suggests a stronger, more effective urinary stream which was judged by women to  
262 contradict the term "weak". The term "ralenti" ("slowed" in English) was therefore chosen  
263 to remain faithful to the original meaning.

264 The questionnaire showed stable results over time, during the test-retest, with an  
265 acceptable intraclass correlation coefficient in all sections of the FPFQ. Average difference  
266 did not exceed 10% between the two assessments. Our hypothesis is that a variation of less  
267 than 10% is not clinically significant as the smallest significant variation in quality of life was  
268 estimated at 15% for other surveys on the same subject (8). Despite high response  
269 consistency during the test-retest, weighted kappa coefficients were poor for certain issues.  
270 This result is explained by a low prevalence of certain responses because overall, sample No.  
271 1 was not particularly symptomatic. The kappa coefficient is very sensitive to frequency of  
272 response and the extreme modalities of certain questions were never indicated (24).  
273 Response consistency was lower among the most symptomatic women according to the  
274 Bland-Altman test. This result can be explained by the fact that bladder and bowel  
275 symptoms are closely related to lifestyle and therefore likely to change over a short period  
276 of time in the absence of medical or surgical intervention.

277 The results of the FPFQ were strongly correlated with those of other symptom  
278 questionnaires (ICIQ-UISF, IPSS and PFDI-20). This result was also observed with specific  
279 quality of life reference tests (Contilife and PFIQ-7). It demonstrates that the French version  
280 of the FPFQ measures the same concept as the reference tests. These correlations were  
281 much higher than we had predicted. We found strong correlations for different areas; for  
282 example, the bowel section of the FPFQ was strongly correlated with the prolapse section of  
283 the PFDI-20 ( $r = 0.6$ ) and the bladder section PFIQ-7 ( $r = 0.5$ ). This result highlights common

284 association of different symptoms for the same woman (3). The interdependence between  
285 sections highlights the importance of symptom assessment in general with multidisciplinary  
286 care in clinical practice.

287 Longitudinal follow-up of 3PN patients highlighted identical score kinetics for the FPFQ and  
288 most other reference tests (ICIQ-UI-SF, Contilife and PFDI-20). Changes in symptomatology  
289 recorded by the FPFQ (RMS significant) and correlations between score differences  
290 measured by the FPFQ and those measured by the ICIQ-UI-SF and the Contilife PFDI-20  
291 reflect good responsiveness. These correlations were weaker between the FPFQ and PFIQ-7.  
292 There is a lower sensitivity to change for the PFIQ-7 for PFDI-20, which justifies this  
293 difference in outcome (25).

## 294 **Conclusion**

295 The FPFQ offers an extensive evaluation of bladder, bowel and sexual function, pelvic organ  
296 prolapse. It is self-administered, which makes it a good tool to gather information deemed  
297 embarrassing or taboo. Based on the analysis of its psychometric properties, it is acceptable,  
298 understandable and properly discriminates between topics. Designed, developed and  
299 validated for the community-dwelling women, the questionnaire is an attractive research  
300 tool in this context. Its responsiveness allows it to be used as an evaluative instrument in  
301 multicenter clinical trials or in the longitudinal monitoring of patients, or measuring  
302 physiological changes during the life of a woman. These studies can be undertaken  
303 internationally as the FPFQ exists in English, German and French.

304 **Thanks**

305 We thank Kaven Baessler as well as all those who contributed to data collection, especially  
306 the 3PN team and Ms. Pascale Fritel. We extend our thanks to Mrs. Sylvie Guinot-Bujon and  
307 Professor Pierre Ingrand for their logistical and material support.

308

- 310 1. Wu JM, Vaughan CP, Goode PS, Redden DT, Burgio KL, Richter HE, et al. Prevalence and trends of symptomatic  
311 pelvic floor disorders in U.S. women. *Obstet Gynecol* 2014;123:141-8.
- 312 2. Smith FJ, Holman CD, Moorin RE, Tsokos N. Lifetime risk of undergoing surgery for pelvic organ prolapse. *Obstet*  
313 *Gynecol* 2010;116:1096-100.
- 314 3. Bradley CS, Kennedy CM, NYgaard IE. Pelvic floor symptoms and lifestyle factors in older women. *J Womens*  
315 *Health* 2005;14:128-36.
- 316 4. Su C-C, Sun BY-C, Jiann B-P. Association of urinary incontinence and sexual function in women. *Int J Urol*  
317 2015;22:109-13.
- 318 5. Wiskind AK, Creighton SM, Stanton SL. The incidence of genital prolapse after the Burch colposuspension. *Am J*  
319 *Obstet Gynecol* 1992;167:399-404.
- 320 6. Avery K, Donovan J, Peters T, Shaw C, Gotoh M, & Abrams P. ICIQ: a brief and robust measure for evaluating the  
321 symptoms and impact of urinary incontinence. *Neurourol Urodyn* 2004;23:322-30.
- 322 7. Bonniaud V, Raibaut P, Guyatt G, Amarenco G, Parratte B. Scores de symptômes et de qualité de vie au cours des  
323 troubles vésicosphinctériens [Symptom and quality of life assessment in urinary disorders]. *Ann Readapt Med*  
324 *Phys* 2005;48:392-403.
- 325 8. Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women  
326 with pelvic floor disorders (PFDI-20 and PFIQ-7). *Am J Obstet Gynecol* 2005;19:103-13.
- 327 9. Avery KNL, Bosch JLHR, Gotoh M, Naughton M, Jackson S, Radley SC, et al. Questionnaires to assess urinary and  
328 anal incontinence: review and recommendations. *J Urol* 2007;177:39-49.
- 329 10. Khoo SK, O'Neill S, Travers C, Oldenburg B, LAW Study Group. Age-related changes relevant to health in women:  
330 design, recruitment, and retention strategies for the Longitudinal Assessment of Women (LAW) study. *J Womens*  
331 *Health* 2008;17:135-46.
- 332 11. Baessler K, O'Neill SM, Maher CF, Battistutta D. An interviewer-administered validated female pelvic floor  
333 questionnaire for community-based research. *Menopause* 2008;15:973-7.
- 334 12. Baessler K, O'Neill SM, Maher CF, Battistutta D. A validated self-administered female pelvic floor questionnaire.  
335 *Int Urogynecol J* 2010;21:163-72.
- 336 13. Baessler K, Kempkensteffen C. Validierung eines umfassenden Beckenboden-Fragebogens für Klinik, Praxis und  
337 Forschung [Validation of a comprehensive pelvic floor questionnaire for the hospital, private practice and  
338 research]. *Gynakol-Geburtshilfliche Rundsch* 2009;49:299-307.
- 339 14. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. *Ann Intern Med* 1993;118:622-9.
- 340 15. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-  
341 report measures. *Spine* 2000;25:3186-91.
- 342 16. Fritel X, de Tayrac R, Bader G, Savary D, Gueye A, Deffieux X, Fernandez H, Richet C, Guilhot J, Fauconnier A.  
343 Preventing Urinary Incontinence With Supervised Prenatal Pelvic Floor Exercises: A Randomized Controlled Trial.  
344 *Obstet Gynecol* 2015;126. DOI: 10.1097/AOG.0000000000000972
- 345 17. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. *Statistics and*  
346 *strategies for evaluation. Control Clin Trials* 1991;12:142S-58S.
- 347 18. Koch GG, Landis JR, Freeman JL, Freeman DH Jr, Lehnen RC. A general methodology for the analysis of  
348 experiments with repeated measurement of categorical data. *Biometrics* 1977;33:133-58.
- 349 19. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical  
350 measurement. *Lancet* 1986;1:307-10.
- 351 20. Bonniaud V, Jackowski D, Parratte B, Paulseth R, Grad S, Margetts P, Guyatt G. Quality of Life in Multiple Sclerosis  
352 Patients with Urinary Disorders: Discriminative Validation of the English Version of Qualiveen. *Qual life Res*  
353 2005;14:425-31.
- 354 21. Fritel X. Périnée et grossesse [Pelvic floor and pregnancy]. *Gynecol Obstet Fertil* 2010;38:332-46.
- 355 22. Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A. Responsiveness and validity in health status  
356 measurement: a clarification. *J Clin Epidemiol* 1989;42:403-8.
- 357 23. McDonald EA, Brown SJ. Does method of birth make a difference to when women resume sex after childbirth?  
358 *BJOG* 2013;120:823-30.
- 359 24. Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. *J Clin Epidemiol* 1993;46:423-9.
- 360 25. Barber MD, Walters MD, Cundiff GW, PESSRI Trial Group. Responsiveness of the Pelvic Floor Distress Inventory  
361 (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ) in women undergoing vaginal surgery and pessary treatment  
362 for pelvic organ prolapse. *Am J Obstet Gynecol* 2006;194:1492-8.
- 363

364 **Tables and figures**

365 Table I Reliability - Internal consistency: Scores obtained in the FPFQ by sample No. 1 women in the  
366 test-retest; intraclass correlation coefficient (ICC) and its confidence interval 95% (95% CI ICC);  
367 Cronbach alpha coefficient calculated on the data collected during the first assessment.

368 \* In the test-retest, 56 women completed the FPFQ once and 51 completed the questionnaire twice  
369 (a month apart.)

370 \*\* The sex score of the FPFQ was calculated twice for 34 women. Of these, 3 were not sexually  
371 active because of pelvic floor disorders in at least one of the two assessments; the maximum score  
372 of 10 was assigned to this section. Seventeen women were not sexually active for reasons not  
373 related to pelvic floor disorders in at least one of the two assessments. For these women, no mean  
374 difference for the sex subscore was calculate.

375

376

377 Table II Internal consistency: Scores obtained in the FPFQ by patients in the 3PN clinical trial and  
378 Cronbach alpha coefficients calculated at baseline (n = 272\*).

379 Missing data higher than 2 for each sub-score did not allow the calculation of that sub-score. In the  
380 absence of a sub-score, the total score was not calculated.

381 \*Ten women included in the trial did not complete the questionnaires.

382 \*\* The sexsubscore could be calculated for 232 women. Of these, 4 were not sexually active because  
383 of pelvic floor disorders; the maximum score of 10 points was assigned to this section of the  
384 questionnaire. Nineteen women were not sexually active in the sample for reasons not related to  
385 pelvic floor disorders.

386

387

388 Table III Construct Validity: Correlations between FPFQ scores on inclusion from patients enrolled in  
389 the 3PN study at Nîmes CHU (n = 71); Spearman correlation coefficient.

390

391

392 Figure 1: Representation of the difference in Total score of the test-retest based on mean score, as  
393 calculated by the Bland-Altman method - Sample No. 1 (n = 51)

394

395

396 Figure 2: Evolution of scores and sub-scores obtained in the FPFQ, the ICIQ-UI-SF, Contilife, the PFDI-  
397 20 and PFIQ-7 during longitudinal monitoring of 3PN patients recruited at Nîmes CHU (n = 71).

398 \*The PFDI-20 and PFIQ-7 sub-scores are out of 100 points (UDI-6 CRADI-8 POPDI-6, UIQ-7 CRAIQ-7  
399 POPIQ-7), the ICIQ-UI-SF is out of 21 points. These scores were reduced 10 to facilitate comparison  
400 with FPFQ subscores.

401 \*\*Contilife is given a score out of 10 points and is inversely proportional to the FPFQ Bladder  
402 subscore. The graph shows the difference between the maximum score (10) and the score obtained  
403 by the subject.

404 \*\*\*The PFDI-20 and PFIQ -7 are scored out of 300 points. These scores were reduced 40 to facilitate  
405 comparison with the total FPFQ score.